Neuroinflammation in Alzheimer's disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25792098.
- Also identified by DOI 10.1016/S1474-4422(15)70016-5 and PMC identifier 5909703.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer's disease.
Medical subject headings
- Alzheimer Disease
- Anti-Inflammatory Agents, Non-Steroidal
- Brain Injuries
- Immunity, Innate
- Inflammation
- Inflammation Mediators
- Microglia
- Obesity